Release
Date: April 9 2013
Responses Due: May 15, 2013
National Heart, Lung, and Blood Institute (NHLBI)
This Request for Information (RFI) seeks to identify clinical investigators, business entities and/or medical facilities in or with access to low resource settings to support Phase II and Fast-Track Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) studies to test a Point of Care (POC) device for the diagnosis of Sickle Cell Disease (SCD). This information will be used to assess the current state of the field and identify potential entities with the interest and expertise to engage in this research.
The National Heart, Lung, and Blood Institute intends to utilize the SBIR/STTR mechanism to promote the development of a POC device for the diagnosis of SCD in low resource settings. During Phase I, innovative technologies for SCD diagnosis will be developed and tested for their feasibility. In Phase II, the device will be tested in a targeted population in the low resource setting. The aim of this notice is to identify companies/investors/low-resource setting health providers who are willing and capable of collaborating with companies/entities seeking such collaboration during the Phase II portion of the project.
Please comment by identifying entities that might be interested in supporting evaluation of a POC device to diagnose SCD in infants and children in low resource settings and suggesting potential relevant capabilities. The list of these prospective parties will be shared with companies/entities seeking such support.
Responses to this RFI are voluntary. Any personal identifiers (e.g., names, addresses, email addresses, etc.) will be removed when responses are compiled. Only the de-identified comments will be used. Proprietary, classified, confidential, or sensitive information should not be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)
This RFI is for information and planning purposes only and should not be construed as a solicitation or as an obligation on the part of the Government to provide support for any ideas identified in response to it. Please note that the United States Government will not pay for the preparation of any information submitted or for its use of that information. Responses will be compiled and shared internally and with the National Heart, Lung, and Blood Advisory Council, with one or more subcommittees of the Council, and with scientific working groups convened by the NHLBI, as appropriate. In all cases where responses are shared, the names of the respondents will be withheld.
We look forward to your input and hope that you will share this document with your colleagues. Thank you very much for your help.
Interested extramural investigators and other interested parties are invited to respond.
Responses to the RFI will be accepted until May 15, 2013. You will not receive individualized feedback on any suggestions. No basis for claims against the United States government shall arise as a result of a response to this request for information or from the United States government's use of such information.
Responses should be submitted via email to: hanspalm@nhlbi.nih.gov
Please
direct all inquiries to:
Manjit Hanspal, Ph.D.,
National
Heart, Lung, and Blood Institute
6701
Rockledge Drive, MSC 7950, Room 9158
Bethesda,
MD 20892-7950
Telephone: 301-435-0050
Email: hanspalm@nhlbi.nih.gov
and Human Services (HHS)
